Tiziana Life Sciences Ltd (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, announced today that it will host a virtual Key Opinion Leader (KOL) webinar event, “Foralumab Clinical Update in Multiple Sclerosis: A Landmark .
Serum neurofilament light chain and glial fibrillary acidic protein levels can help improve outcome predictions in multiple sclerosis and are linked to relapse risk after treatment discontinuation.
Paramagnetic rim lesions on MRI show a high specificity for a diagnosis of multiple sclerosis; and higher numbers of the lesions are associated with worse disability, new research suggests.